ArticleCancers2025

Assessment of Objective Response Rate by Investigator vs. Blinded Independent Central Review in Pivotal Trials of Oncology Drugs for Solid Tumor Indications.

Marjorie E ZettlerPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.